Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

被引:3
|
作者
Muchtar, Eli [1 ]
Wisniowski, Brendan [2 ]
Geyer, Susan [3 ]
Palladini, Giovanni [4 ,5 ]
Milani, Paolo [4 ,5 ]
Merlini, Giampaolo [4 ,5 ]
Schoenland, Stefan [6 ]
Veelken, Kaya [6 ]
Hegenbart, Ute [6 ]
Leung, Nelson [1 ]
Dispenzieri, Angela [1 ]
Kumar, Shaji K. [1 ]
Kastritis, Efstathios [7 ]
Dimopoulos, Meletios A. [7 ]
Liedtke, Michaela [8 ]
Ulloa, Patricia [8 ]
Sanchorawala, Vaishali [9 ]
Szalat, Raphael [9 ]
Dooley, Katharine [3 ]
Landau, Heather [10 ]
Petrlik, Erica [10 ]
Lentzsch, Suzanne [11 ]
Coltoff, Alexander [11 ]
Blade, Joan [12 ]
Cibeira, M. Teresa [12 ]
Cohen, Oliver [2 ]
Foard, Darren [2 ]
Gillmore, Jullian [2 ]
Lachmann, Helen [2 ]
Wechalekar, Ashutosh [2 ]
Gertz, Morie A. [1 ]
机构
[1] Mayo Clin, Div Hematol, 200 First St,SW, Rochester, MN 55905 USA
[2] Univ Coll London Med Sch, Natl Amyloidosis Ctr, Royal Free Hosp Campus, London, England
[3] Mayo Clin, Div Clin Trials & Biostat, Rochester, MN 55905 USA
[4] Univ Pavia, Dept Mol Med, Pavia, Italy
[5] Univ Pavia, Fdn IRCCS Policlin San Matteo, Amyloidosis Res & Treatment Ctr, Pavia, Italy
[6] Heidelberg Univ, Amyloidosis Ctr, Med Dept 5, Heidelberg, Germany
[7] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece
[8] Stanford Univ, Sch Med, Stanford Amyloid Ctr, Stanford, CA USA
[9] Boston Univ, Amyloidosis Ctr, Boston Med Ctr, Sect Hematol & Oncol,Sch Med, Boston, MA USA
[10] Mem Sloan Kettering Canc Ctr, Div Hematol Oncol, New York, NY USA
[11] Columbia Univ, Med Ctr, Div Hematol Oncol, New York, NY USA
[12] Inst Invest Biomed August Pi i Sunyer, Hosp Clin, Dept Hematol, Barcelona, Spain
基金
美国国家卫生研究院;
关键词
AL AMYLOIDOSIS; RENAL-RESPONSE; OUTCOMES;
D O I
10.1001/jamaoncol.2024.2629
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Importance Kidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes. Objective To validate graded kidney response criteria and their association with kidney and overall survival (OS). Design, Setting, and Participants This retrospective, multicenter cohort was conducted at 10 referral centers for amyloidosis from 2010 to 2015 and included patients with kidney AL amyloidosis that was evaluable for kidney response and who achieved at least hematologic partial response within 12 months of diagnosis. The median follow-up was 69 (54-88) months. Data analysis was conducted in 2023. Exposure Four kidney response categories based on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (kidCR, 24-hour UP <= 200 mg), very good partial response (kidVGPR, >60% reduction in 24-hour UP), partial response (kidPR, 31%-60% reduction), and no response (kidNR, <= 30% reduction). Kidney response was assessed at landmark points (6, 12, and 24 months) and best kidney response. Main Outcomes and Measures Cumulative incidence of progression to KRT and OS. Results Seven-hundred and thirty-two patients (335 women [45.8%]) were included, with a median (IQR) age of 63 (55-69) years. The median (IQR) baseline 24-hour proteinuria and estimated glomerular filtration rate was 5.3 (2.8-8.5) g per 24 hours and 72 (48-92) mL/min/1.73m(2), respectively. In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreased with deeper kidney responses as early as 6 months from therapy initiation (11%, 12%, 2.1%, and 0% for kidNR, kidPR, kidVGPR, and kidCR, respectively; P = .002) and were maintained at 12 months and 24 months and best kidney response. Patients able to achieve kidCR/kidVGPR by 24 months and at best response had significantly better OS compared with kidPR/kidNR. Kidney progression, defined as a 25% or greater decrease in estimated glomerular filtration rate, was associated with cumulative incidence of progression to KRT and OS. Conclusions and Relevance The results of this cohort study suggest that graded kidney response criteria offers clinically and prognostically meaningful information for treating patients with kidney AL amyloidosis. The response criteria potentially inform kidney survival based on the depth of reduction in 24-hour proteinuria levels and demonstrate an OS advantage for those able to achieve kidCR/kidVGPR compared with kidPR/kidNR. Taken together, achievement of at least kidVGPR by 12 months is needed to ultimately improve kidney and patient survival.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis
    Muchtar, Eli
    Wisniowski, Brendan
    Palladini, Giovanni
    Milani, Paolo
    Merlini, Giampaolo
    Schonland, Stefan
    Veelkan, Kaya
    Hegenbart, Ute
    Dispenzieri, Angela
    Kumar, Shaji
    Leung, Nelson
    Kastritis, Efstathios
    Dimopoulos, Meletios-Athanasios
    Liedtke, Michaela
    Witteles, Ronald
    Sanchorawala, Vaishali
    Szalat, Raphael
    Landau, Heather
    Lentzsch, Suzanne
    Blade, J.
    Cibeira, M. T.
    Cohen, Oliver
    Foard, Darren
    Wechalekar, Ashutosh
    Gertz, Morie
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S23 - S24
  • [2] Graded Renal Response Criteria for Light Chain (AL) Amyloidosis
    Muchtar, Eli
    Wisniowski, Brendan
    Palladini, Giovanni
    Milani, Paolo
    Merlini, Giampaolo
    Schoenland, Stefan
    Veelken, Kaya
    Hegenbart, Ute
    Dispenzieri, Angela
    Kumar, Shaji
    Leung, Nelson
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    Liedtke, Michaela
    Witteles, Ronald
    Sanchorawala, Vaishali
    Szalat, Raphael
    Landau, Heather J.
    Petrlik, Erica
    Lentzsch, Suzanne
    Coltoff, Alexander
    Blade, Joan
    Teresa Cibeira, M.
    Cohen, Oliver C.
    Foard, Darren
    Gillmore, Julian D.
    Lachmann, Helen J.
    Wechalekar, Ashutosh D.
    Gertz, Morie A.
    [J]. BLOOD, 2021, 138
  • [3] Immunoglobulin light chain amyloidosis and the kidney
    Gertz, MA
    Lacy, MQ
    Dispenzieri, A
    [J]. KIDNEY INTERNATIONAL, 2002, 61 (01) : 1 - 9
  • [4] Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis
    Muchtar, Eli
    Dispenzieri, Angela
    Wisniowski, Brendan
    Palladini, Giovanni
    Milani, Paolo
    Merlini, Giampaolo
    Schoenland, Stefan
    Veelken, Kaya
    Hegenbart, Ute
    Geyer, Susan M.
    Kumar, Shaji K.
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    Liedtke, Michaela
    Witteles, Ronald
    Sanchorawala, Vaishali
    Szalat, Raphael
    Landau, Heather
    Petrlik, Erica
    Lentzsch, Suzanne
    Coltoff, Alexander
    Blade, Joan
    Cibeira, Maria Teresa
    Cohen, Oliver
    Foard, Darren
    Wechalekar, Ashutosh
    Gertz, Morie A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (07) : 1393 - +
  • [5] Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study
    Muchtar, Eli
    Palladini, Giovanni
    Schonland, Stefan
    Dispenzieri, Angela
    Wisniowski, Brendan
    Merlini, Giampaolo
    Milani, Paolo
    Hegenbart, Ute
    Dittrich, Tobias
    Kastritis, Efstathios
    Dimopoulos, Meletios Athanasios
    Sanchorawala, Vaishali
    Szalat, Raphael E.
    Liedtke, Michaela
    Gupta, Mani
    Landau, Heather
    Lentzsch, Suzanne
    Hughes, Michael Sang
    Cibeira Lopez, Maria Teresa
    Blade, Joan
    Kumar, Shaji Kunnathu
    Wechalekar, Ashutosh D.
    Gertz, Morie A.
    [J]. BLOOD, 2023, 142
  • [6] Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?
    Jain, Ankur
    Ramasamy, Karthik
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (10): : E769 - E776
  • [7] Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Gertz, Morie A.
    Leung, Nelson
    Lacy, Martha Q.
    Dispenzieri, Angela
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dingli, David
    Greipp, Philip R.
    Kumar, Shaji K.
    Lust, John A.
    Rajkumar, S. Vincent
    Russell, Stephen J.
    Witzig, Thomas E.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (10) : 3132 - 3137
  • [8] Immunoglobulin light chain amyloidosis
    Merlini, Giampaolo
    Comenzo, Raymond L.
    Seldin, David C.
    Wechalekar, Ashutosh
    Gertz, Morie A.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (01) : 143 - 156
  • [9] The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis
    Angel-Korman, Avital
    Jaberi, Aala
    Sanchorawala, Vaishali
    Havasi, Andrea
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2020, 27 (01): : 17 - 24
  • [10] Factors predicting organ response in light chain amyloidosis (AL).
    Sidana, Surbhi
    Tandon, Nidhi
    Dispenzieri, Angela
    Gertz, Morie A.
    Buadi, Francis
    Lacy, Martha
    Dingli, David
    Fonder, Amie L.
    Hayman, Suzanne R.
    Hobbs, Miriam A.
    Gonsalves, Wilson I.
    Hwa, Yi Lisa
    Kapoor, Prashant
    Kyle, Robert A.
    Leung, Nelson
    Go, Ronald S.
    Lust, John Anthony
    Russell, Stephen J.
    Rajkumar, S. Vincent
    Kumar, Shaji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35